Results 201 to 210 of about 58,467 (222)
Some of the next articles are maybe not open access.
Emerging Antibody-Based HER2 (ErbB-2/neu) Therapeutics
Breast Disease, 2000Targeting HER2(ErbB-2/neu) overexpressing tumor cells to selectively deliver anticancer agents and thereby reduce host toxicity represents a rational and emerging strategy for the treatment of breast and other epithelial cancers. The extracellular domain of the HER2 receptor tyrosine kinase is readily accessible to systemically administered antibody ...
W C, Krauss +4 more
openaire +2 more sources
c-erbB-2 Gene Amplification in Nasopharyngeal Carcinoma
Cancer Investigation, 2000Amplification of the c-erbB-2 gene has been associated with poor prognosis in different types of cancer. However, there are no data on the c-erbB-2 expression levels in nasopharyngeal cancer. In this study, amplification of the gene has been investigated in the tumor tissue of patients with nasopharyngeal cancer by competitive polymerase chain reaction
H, Yazici +4 more
openaire +2 more sources
c- erbB-2 Immunohistochemistry in Paraffin Tumors
2003Immunohistochemistry is the study of the intracellular distribution of antigens based on the formation of an immune complex. The concept is based on the application of a specific antibody to the antigen to be detected and visualization of the antigen-antibody reaction with a staining procedure.
openaire +2 more sources
erbB-2 (HER-2) and Breast Cancer Progression
Applied Immunohistochemistry & Molecular Morphology, 2003The purpose of this study was to explore differences in erbB-2 alterations in recurrent or metastatic disease, as compared with the primary tumor. Primary invasive breast cancers and subsequent local, regional, or distant metastases from 113 patients were examined.
S M, Edgerton +3 more
openaire +2 more sources
ErbB-2 protein levels in healthy, asymptomatic women
Biomarkers, 1996Abstract Recently, a number of studies have found a relationship between having breast cancer and elevated serological levels of the extracellular domain (ECD) of the erbB-2 protein. This study focuses on healthy, asymptomatic women, and evaluates the relationship between serological concentration of the ECD of erbB-2 protein and the following ...
B, Breuer +5 more
openaire +2 more sources
Molecular Immunology, 1991
BCA200 has been described as a 200,000 Mr monomeric cell surface glycoprotein associated with human breast cancer. Since the physical properties and cellular distribution of BCA200 resemble those of c-erbB-2, antibodies to BCA200 were tested for the ability to bind a recombinant protein containing the c-erbB-2 extracellular domain (erbB-2 ECD).
D B, Ring, R, Clark, A, Saxena
openaire +2 more sources
BCA200 has been described as a 200,000 Mr monomeric cell surface glycoprotein associated with human breast cancer. Since the physical properties and cellular distribution of BCA200 resemble those of c-erbB-2, antibodies to BCA200 were tested for the ability to bind a recombinant protein containing the c-erbB-2 extracellular domain (erbB-2 ECD).
D B, Ring, R, Clark, A, Saxena
openaire +2 more sources
Gan to kagaku ryoho. Cancer & chemotherapy, 1994
Sandwich radioimmunometric assay (ErbB-2 IRMA 'Eiken') was developed to determine the levels of c-erbB-2 oncogene product (ErbB-2 protein) in human sera, and a clinical investigation was carried out to evaluate this novel oncogene product. The mean serum concentration of the ErbB-2 protein determined from 364 donors was 4.0 +/- 0.69 ng/ml (mean +/- SD)
K, Sugano +9 more
openaire +1 more source
Sandwich radioimmunometric assay (ErbB-2 IRMA 'Eiken') was developed to determine the levels of c-erbB-2 oncogene product (ErbB-2 protein) in human sera, and a clinical investigation was carried out to evaluate this novel oncogene product. The mean serum concentration of the ErbB-2 protein determined from 364 donors was 4.0 +/- 0.69 ng/ml (mean +/- SD)
K, Sugano +9 more
openaire +1 more source
[Clinical evaluation of serum ErbB-2 protein using enzyme immuno assay (ErbB-2 EIA [Nichirei])].
Gan to kagaku ryoho. Cancer & chemotherapy, 1994The levels of ErbB-2 protein in serum samples from patients with breast cancer, other various malignant tumors, and benign diseases were determined using the sandwich EIA for clinical evaluation. In 364 healthy blood donors, cut-off values were set at 5.4 ng/ml for females and 6.5 ng/ml for males.
K, Sugano +9 more
openaire +1 more source
c-erbB-2 as a target for immunotherapy
Expert Opinion on Investigational Drugs, 1998The c-erbB-2 proto-oncogene encodes a 185 kDa transmembrane Type 1 tyrosine kinase receptor whose amplification and/or overexpression has been linked with poor prognosis in a variety of cancers. The oncoprotein has been suggested to play a key role in tumour cell invasion, motility and metastasis, and in responsiveness to therapeutic agents.
openaire +2 more sources
Seminars in oncology, 1989
The neu gene was first identified in rat tumors that had been induced by the carcinogen ethyl nitrosourea. The human homolog of neu, usually designated c-erbB-2, is located on chromosome 17, q21. It specifies a transmembrane receptor-like phosphoglycoprotein that is closely related to the EGFr (c-erbB-1). The ligand for c-erbB-2 is not known.
H C, Maguire, M I, Greene
openaire +1 more source
The neu gene was first identified in rat tumors that had been induced by the carcinogen ethyl nitrosourea. The human homolog of neu, usually designated c-erbB-2, is located on chromosome 17, q21. It specifies a transmembrane receptor-like phosphoglycoprotein that is closely related to the EGFr (c-erbB-1). The ligand for c-erbB-2 is not known.
H C, Maguire, M I, Greene
openaire +1 more source